Effect of Omecamtiv Mecarbil Combined with Bisoprolol in the Treatment of Patients with Heart Failure with Reduced E-jection Fraction
Objective To explore the clinical effect of omecamtiv mecarbil combined with bisoprolol in the treatment of patients with heart failure with reduced ejection fraction.Methods A total of 435 patients with heart failure with reduced ejection fraction admitted to our hospital from January 2021 to January 2023 were selected and randomly divided into two groups.The control group was treated with bisoprolol,and the observation group was treated with omecamtiv mecarbil on the basis of the control group.The therapeutic effect,cardiac function,and levels of BNP and CRP were compared between the two groups.Results The total effective rate in the observation group was 89.45%,higher than 63.13%in the control group(P<0.05).After treatment,the levels of BNP and CRP in the observation group were lower than those in the control group(P<0.05).After treatment,LVEF and LVEDV in the observation group were higher than those in the control group,and LVESV and LVEDD were lower than those in the control group(P<0.05).Conclusions Omecamtiv mecarbil combined with bisoprolol is effective in the treatment of heart failure with reduced ejection fraction,and can improve the cardiac function of patients.
Omecamtiv mecarbilBisoprololHeart failure with reduced ejection fractionCardiac function
国家科技期刊平台
NSTL
万方数据
维普
